Burning Rock Biotech Ltd (BNR) Form 6-K — Sep 10, 2026
Burning Rock Biotech reported Q2 2026 revenue of RMB134.7 million (US$19.9 million), down 9.3% from RMB148.5 million a year earlier, but up sharply from RMB107.9 million in Q1 2026 as management said it delivered an anticipated sequential recovery after first-quarter order volatility. Profitability moved the wrong way: net loss widened to RMB18.4 million (US$2.7 million) from RMB9.7 million in Q2 2025. By channel, in-hospital revenue grew 7.4% YoY to RMB67.1 million, while central laboratory revenue fell 10.0% and pharma R&D services dropped 31.8% on reduced testing volumes.
Key figures
- Eps
- RMB(0.17) / US$(0.02) basic and diluted per share
- Revenue
- RMB134.7 million (US$19.9 million)
- Net Income
- Net loss of RMB18.4 million (US$2.7 million) vs RMB9.7 million net loss in Q2 2025
- Total Debt
- RMB1.8 million total borrowings (RMB0.2 million current portion + RMB1.6 million long-term)
- Revenue Yoy
- -9.3%
- Total Assets
- RMB750.6 million (US$110.6 million)
- Cash Position
- RMB419.1 million (US$61.8 million) in cash, cash equivalents and restricted cash as of June 30, 2026
- Fx Rate Used
- RMB6.7851 per US$1.00 (June 30, 2026)
- Rd Expenses
- RMB31.2 million, -37.3% YoY
- Gross Margin
- 72.6% vs 72.8% a year ago
- Partner Hospitals
- 94
- Pharma Rn DRevenue
- RMB30.8 million (US$4.6 million), -31.8% YoY
- Central Lab Revenue
- RMB36.8 million (US$5.4 million), -10.0% YoY
- In Hospital Revenue
- RMB67.1 million (US$9.9 million), +7.4% YoY
- Operating Expenses
- RMB115.8 million (US$17.1 million), -3.2% YoY
- Non Gaa PGross Margin
- 74.3% vs 74.4% a year ago
- Operating Cash Use H1
- RMB51.7 million (US$7.6 million) net cash used in operations in H1 2026
- Shareholders Equity
- RMB497.1 million (US$73.3 million)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.